Because our aim was to compare the outcomes of KRAS codon 12 and 13 mutant cases with those characterized by other mutations, clinical data and FFPE specimens of the patients treated with cetuximab-containing regimens at seven Japanese cancer centers from July 2008 to April 2010 were collected. The gene discussed is KRAS; the disease is cancer.